This presentation preceded Vicor's receipt of 510(k) clearance from the U.S. Food and Drug Administration for its PD2i® nonlinear algorithm and software to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration in patients specifically undergoing cardiovascular disease testing.

In addition to Mr. Fater, Vicor Technologies' representatives in attendance during Dr. Zareba's poster presentation were Jerry Anchin, PhD, Vicor Vice President and Director of Product Development; Daniel Weiss, MD, FACC, Vicor Chief Medical Officer; and Edward Lundy, MD, PhD, Chief of Cardiothoracic Surgery, Active International Cardiovascular Institute at Good Samaritan Hospital and Chairman of Vicor's Scientific Advisory Board.


"We're extremely pleased and honored to have had Dr. Zareba, a world-renowned researcher and enthusiastic supporter of our PD2i® nonlinear algorithm and software, make this presentation of our MUSIC Trial data at the American College of Cardiology 60th Annual Scientific Session and i2 Summit. We are excited by the attention the PD2i® nonlinear algorithm and software received from researchers interested in exploring its use for applications in other cardiac disease states and from clinicians interested in adding a diagnostic that enables accurate measurement of heart rate variability to determine the health of the autonomic nervous system as a means of identifying potential health risks," Mr. Fater stated.

"Throughout the Scientific Session, there was a focus on the importance of risk stratification, the need for accurate risk stratification, and the importance of the autonomic nervous system in cardiac disease. The PD2i® has demonstrated the ability to accurately measure heart rate variability -- a measure for autonomic nervous system health -- which suggests it is well positioned to provide the cardiology community with a valuable new diagnostic for risk stratifying heart failure patients," stated Dr. Weiss.

"The MUSIC Trial study results presented by Dr. Zareba represent good news for congestive heart failure patients who would benefit from a diagnostic that accurately identifies those at greatest risk for death and thus derive maximal benefit from more comprehensive care and possible earlier initiation of resynchronization therapy. Importantly, they are not the only population that will benefit from Vicor's PD2i® nonlinear algorithm; this is just another one of more than 45 independent studies documenting the predictive value of the PD2i® nonlinear algorithm for use in risk stratifying patients for a variety of clinical disorders and conditions," stated Dr. Lundy.

More HCB News